Related Experiment Videos
Tetravalent rhesus rotavirus vaccine in young infants
M Kobayashi1, J Thompson, S J Tollefson
1Department of Pediatrics, Vanderbilt University, Nashville, Tennessee.
Insights
This study found that a tetravalent rhesus rotavirus vaccine (RRV-TV) was infectious in infants but primarily elicited immune responses to the parent rhesus strain, not all vaccine components.
Area of Science:
- Vaccinology
- Virology
- Pediatric Infectious Diseases
Background:
- Rotavirus is a leading cause of severe diarrheal disease in infants globally.
- Live oral rotavirus vaccines are a key strategy for prevention.
- Evaluating novel vaccine formulations, like tetravalent rhesus rotavirus vaccine (RRV-TV), is crucial.
Purpose of the Study:
- To assess the safety, viral shedding, and immunogenicity of a tetravalent live oral rhesus rotavirus vaccine (RRV-TV) in healthy infants.
- To understand the immune response profile to a polyvalent rotavirus vaccine formulation.
Main Methods:
- A double-blind, placebo-controlled study involving 26 healthy infants aged 6-22 weeks.
- The RRV-TV contained equal amounts of RRV (serotype 3) and VP7 reassortants (serotypes 1, 2, and 4).
- Evaluation included safety monitoring, viral shedding analysis, and assessment of humoral and mucosal immune responses.
Main Results:
- RRV-TV was highly infectious, with 16 of 18 recipients shedding virus, predominantly the parent rhesus strain (RRV).
- Humoral immune responses were mainly directed against the RRV strain, with a consistent ELISA IgM response observed in 14 of 18 vaccinees.
- No significant mucosal antibody responses were detected.
Conclusions:
- The tetravalent rhesus rotavirus vaccine (RRV-TV) demonstrated infectivity but elicited a limited immune response, primarily to the parent rhesus strain.
- Factors such as infant age, maternal antibodies, specimen timing, or vaccine polyvalence may have influenced the restricted immune response.
- Further research is needed to optimize rotavirus vaccine immunogenicity in infants.
Abstract:
A study of a tetravalent live oral rhesus rotavirus vaccine was conducted in 26 healthy infants 6-22 weeks of age to evaluate safety, viral shedding, and immunogenicity in a double-blind, placebo-controlled fashion. The tetravalent rhesus rotavirus vaccine (RRV-TV) contained equal amounts of RRV (serotype 3) and the VP7 reassortants DxRRV (serotype 1), DS1xRRV (serotype 2), and ST3xRRV (serotype 4). RRV-TV was highly infectious; 16 of 18 recipients shed virus. However, the recovered virus was almost exclusively the parent rhesus strain, RRV. Humoral immune responses were largely limited to the RRV strain. The most consistent response, seen in 14 of 18 vaccines, was an ELISA IgM response to purified RRV. Mucosal antibody responses were not seen. The limited immune response may be a function of age, presence of maternal antibody, timing of the convalescent specimens, or the polyvalent nature of the vaccine.